The Committee for Medicinal Products for Human Use (CHMP) is the committee at the European Medicines Agency that is responsible for preparing opinions on questions concerning medicines for human use.
The CHMP replaced the former Committee for Proprietary Medicinal Products (CPMP).
- See the full overview of the CHMP's role
The members and alternates of the CHMP are nominated by European Union Member States in consultation with the Agency's Management Board. They are chosen on the strength of their qualifications and expertise with regard to the evaluation of medicines.
They serve on the Committee for a renewable period of three years.
The CHMP is composed of:
- a chair, elected by serving CHMP members;
- one member and an alternate nominated by each of the 28 Member States;
- one member and an alternate nominated by Iceland and by Norway;
- up to five co-opted members, chosen among experts nominated by Member States or the Agency and recruited, when necessary, to provide additional expertise in a particular scientific area.